自己輸血システムの世界市場2023-2030

自己輸血システムの世界市場は、予測期間中にCAGR 5.6%で成長すると推定されます。市場成長の主な要因としては、手術件数の増加、臓器移植需要の増加、患者の血液管理への注目の高まりなどが挙げられます。臓器移植手術の件数は年々増加しています。例えば、Global Observatory on Donation and Transplantation（GODT）によると、2017年に移植された臓器の数は139,024であり、2015年よりも7.3%増加しました。2017年には1時間あたり16件の移植が行われました。このうち腎臓移植は90,306件、肝臓移植は32,348件が2017年に行われました。このような臓器移植需要の高まりは、臓器移植手術中の患者の血液管理のための自己血輸血の需要増につながっています。

自己血輸血は、血液不足と輸血の安全性に関する懸念の高まりにより、ますます重要性を増しています。血液保存法、輸血医学、血液成分分離技術の進歩、臨床ニーズの継続的な増加に伴い、ABT技術の範囲は大幅に拡大し、革新されています。臓器移植術における出血管理には大きなニーズがあります。その結果、同種輸血の有害な影響の発生を最小限に抑える戦略として自家輸血が利用されています。この方法は、提供血液の極端な使用を避けるために採用されています。

術前自己血輸血では、患者の血液を採取し、しばらく保存します。生体肝移植の場合は別として、肝移植の時期が決まっていないため、事前の採血は通常不可能です。そこで、自己血輸血の戦略として、術中血液救済自己血輸血（IBSA）が採用されています。IBSAでは、手技中に失われた血液を回収し、輸液によって患者の体内に戻します。これにより、レシピエントの生存や免疫抑制効果に影響を及ぼす可能性のある同種輸血の必要性がなくなります。同種輸血は、患者間のウイルス感染や輸血過誤のリスクを高める。そのため、臓器移植手術において、出血量を管理し、手術中の安全性と有効性を高めるための自己輸血システムの需要が高まっています。

セグメント別展望

心臓手術が用途別セグメントで大きなシェアを占める

心臓手術件数の増加と手術中の大量出血が、主に心臓手術における自己輸血システムの需要を強化しています。自己血輸血は、心肺バイパスや開心術の術後期間において、血液を節約し輸血の必要性を最小限に抑えるための簡単で貴重なコンセプトです。これは成人心臓手術における同種血液製剤の必要性を最小限にするものです。術前自己血は同種輸血の安全で効率的な選択肢です。希少な血液型や同種抗体に罹患している患者は、適合する同種血液が常に入手できるとは限らないため、自己血輸血の恩恵を受けることが期待されます。

同種輸血には潜在的な合併症が伴いますが、自己血輸血中に除去または軽減することができます。これらの合併症には、同種免疫、輸血感染症、溶血反応、アレルギー反応、発熱反応などが含まれます。心肺バイパスを行う前に自己血の回収を行うことで、赤血球量を維持し、血小板を保護し、同種輸血の必要性を減少させることができます。自己血提供の適切な条件は、輸血の可能性が高い待機的心臓手術です。

地域別展望

アジア太平洋地域は予測期間中に大きな成長が見込まれる

アジア太平洋地域は、複数の専門病院が増加し、整形外科やCVDの罹患率が上昇していることから、予測期間中に著しい成長を示すと予測されます。また、医療ツーリズムの拡大が同地域の市場成長の機会を提供すると予想されます。India Brand Equity Foundation（IBEF）は、2017年のインドの医療ツーリズム市場は30億米ドルと推定しています。2018年から2019年にかけて、インドの医療ツーリズム市場は、医療ビザ承認のためのより容易な規範のおかげで倍増すると予想されます。インドで医療ビザを取得した外国人旅行者数（FTA）は前年比15.9％増加し、2016年の427,014人から2017年には推定495,056人となっています。

インドでは、国際合同委員会（JCI）-認定病院が21あり、大きく成長しています。インドにおける熟練した小児科専門家の存在は、先天性心疾患市場の前向きな需要にさらに起因しています。Indian Pediatricsによると、現在インドには約130人の小児心臓専門医と110人の小児心臓外科医がいます。世界的に多くの乳児が先天性心疾患を持って生まれているため、熟練した心臓外科医と費用対効果の高い信頼できる治療が利用できることが、同国における医療ツーリズムの成長に寄与していると推定されます。その結果、病院は患者の安全性を重視するようになり、患者の血液を管理する自己輸血システムの需要に貢献しています。

目次

第1章 レポート概要

• 業界の現状分析と成長ポテンシャルの展望
• 調査方法とツール
• 市場内訳
  • セグメント別
  • 地域別

第2章 市場概要と洞察

• 調査範囲
• アナリストの洞察と現在の市場動向
  • 主な調査結果
  • 推奨事項
  • 結論

第3章 競合情勢

• 主要企業分析
• Medtronic plc
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Fresenius KabiAG
  • 会社概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Becton, Dickinson& Co.
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• LivaNova PLC
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• B. Braun Melsungen AG
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• 主要戦略分析

第4章 市場セグメンテーション

• 自己輸血システムの世界市場：用途別
  • 整形外科
  • 心臓外科
  • 外傷処置
  • 臓器移植
  • その他の手技
• 自己輸血システムの世界市場：タイプ別
  • 自己輸血製品
  • 付属品

第5章 地域別分析

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • スペイン
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 世界のその他の地域

第6章 企業プロファイル

• Advancis Surgical
• Atrium Medical Corp.
• B. Braun Melsungen AG
• Becton, Dickinson and Co.
• Beijing ZKSK Technology Co., Ltd.
• BraileBiomedica
• Brightwake Ltd.
• Ecomed Solutions, LLC
• Fresenius KabiAG
• Gen World Medical Devices
• Getinge AB
• Haemonetics Corp.
• LivaNova PLC
• Medtronic plc
• Palex Medical SA
• RedaxS.p.a.
• Sarstedt Ag & Co. KG
• Stryker Corp.
• Teleflex Inc.
• Terumo Corp.
• Zimmer Biomet Holdings, Inc.

LIST OF TABLES

• 1. GLOBAL AUTOTRANSFUSION SYSTEMS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
• 2. GLOBAL AUTOTRANSFUSION SYSTEMS IN ORTHOPEDIC SURGERY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 3. GLOBAL AUTOTRANSFUSION SYSTEMS IN CARDIAC SURGERY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 4. GLOBAL AUTOTRANSFUSION SYSTEMS IN TRAUMA PROCEDURES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 5. GLOBAL AUTOTRANSFUSION SYSTEMS IN ORGAN TRANSPLANTATION MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 6. GLOBAL AUTOTRANSFUSION SYSTEMS IN OTHER PROCEDURES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 7. GLOBAL AUTOTRANSFUSION SYSTEMS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
• 8. GLOBAL AUTOTRANSFUSION PRODUCTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 9. GLOBAL AUTOTRANSFUSION ACCESSORIES MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2022-2030 ($ MILLION)
• 10. GLOBAL AUTOTRANSFUSION SYSTEMS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2022-2030 ($ MILLION)
• 11. NORTH AMERICAN AUTOTRANSFUSION SYSTEMS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 12. NORTH AMERICAN AUTOTRANSFUSION SYSTEMS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
• 13. NORTH AMERICAN AUTOTRANSFUSION SYSTEMS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
• 14. EUROPEAN AUTOTRANSFUSION SYSTEMS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 15. EUROPEAN AUTOTRANSFUSION SYSTEMS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
• 16. EUROPEAN AUTOTRANSFUSION SYSTEMS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
• 17. ASIA-PACIFIC AUTOTRANSFUSION SYSTEMS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 18. ASIA-PACIFIC AUTOTRANSFUSION SYSTEMS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
• 19. ASIA-PACIFIC AUTOTRANSFUSION SYSTEMS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
• 20. REST OF THE WORLD AUTOTRANSFUSION SYSTEMS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
• 21. REST OF THE WORLD AUTOTRANSFUSION SYSTEMS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)

LIST OF FIGURES

• 1. GLOBAL AUTOTRANSFUSION SYSTEMS MARKET SHARE BY APPLICATION, 2022 VS 2030 (%)
• 2. GLOBAL AUTOTRANSFUSION SYSTEMS MARKET SHARE BY TYPE, 2022 VS 2030 (%)
• 3. GLOBAL AUTOTRANSFUSION SYSTEMS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 4. GLOBAL AUTOTRANSFUSION SYSTEMS IN ORTHOPEDIC SURGERY MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 5. GLOBAL AUTOTRANSFUSION SYSTEMS IN CARDIAC SURGERY MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 6. GLOBAL AUTOTRANSFUSION SYSTEMS IN TRAUMA PROCEDURES MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 7. GLOBAL AUTOTRANSFUSION SYSTEMS IN ORGAN TRANSPLANTATION MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 8. GLOBAL AUTOTRANSFUSION SYSTEMS IN OTHER PROCEDURES MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 9. GLOBAL AUTOTRANSFUSION PRODUCTS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 10. GLOBAL AUTOTRANSFUSION ACCESSORIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 11. US AUTOTRANSFUSION SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 12. CANADA AUTOTRANSFUSION SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 13. UK AUTOTRANSFUSION SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 14. FRANCE AUTOTRANSFUSION SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 15. GERMANY AUTOTRANSFUSION SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 16. ITALY AUTOTRANSFUSION SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 17. SPAIN AUTOTRANSFUSION SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 18. ROE AUTOTRANSFUSION SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 19. INDIA AUTOTRANSFUSION SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 20. CHINA AUTOTRANSFUSION SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 21. JAPAN AUTOTRANSFUSION SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 22. REST OF ASIA-PACIFIC AUTOTRANSFUSION SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 23. REST OF THE WORLD AUTOTRANSFUSION SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)

Global autotransfusion systems market is estimated to grow at a CAGR of 5.6% during the forecast period. The major factors contributing to the market growth include the rising number of surgeries, increasing demand for organ transplantation, and emerging focus on patient blood management. The rising number of organ transplantation procedures have witnessed over the years. For instance, as per the Global Observatory on Donation and Transplantation (GODT), in 2017, the number of organs transplanted was 139,024, which increased to 7.3% over 2015. There were 16 transplants per hour in 2017. Of these, 90,306 kidney transplants and 32,348 liver transplants were performed in 2017. This rising demand for organ transplants is leading to increasing demand for autologous blood transfusion for patients' blood management during the organ transplantation procedure.

Autologous blood transfusion has been increasingly gaining significance owing to the growing concerns about blood shortage and blood transfusion safety. With the advances in blood conservation methods, blood transfusion medicine, blood component separation technology, and continuous growth in clinical needs, the scope of ABT technology has been broadened and innovated to a significant extent. There is a significant need for the management of blood loss in organ transplantation procedures. As a result, autologous transfusion is utilized as a strategy to minimize the incidence of the harmful effects of allogeneic transfusion. The method is employed to avoid the extreme use of donated blood.

Preoperative autologous transfusion involves collecting patients' blood and stored for some time. As there is no determined date for liver transplants, excluding cases that involve living donors, blood collection in advance is normally not feasible. Therefore, intraoperative blood salvage autotransfusion (IBSA) is employed as a strategy for autologous transfusion. IBSA involves the recovery of blood loss during the procedure and returns it to the patient's body by infusion. This eliminates the need for an allogeneic blood transfusion which may have an impact on recipient survival and an immunosuppressive effect. Allogeneic transfusion increases the risk of transmission of viral infections and transfusion errors among patients. This, in turn, is contributing to the demand for autotransfusion systems in organ transplant procedures to manage blood loss and increase safety and effectiveness during the procedure.

Segmental Outlook

The global autotransfusion systems market is segmented based on application and type. Based on application, the market is classified into orthopedic surgery, cardiac surgery, trauma procedures, organ transplantation, and other procedures. Based on type, the market is classified into autotransfusion products and accessories.

Cardiac surgeries held a significant share of the application segment

The rising number of cardiac surgeries coupled with significant blood loss during the procedure is primarily strengthening the demand for autotransfusion systems in cardiac surgeries. Autologous transfusion is an easy valuable concept to save blood and minimize the transfusion requirement in the postoperative period in cardiopulmonary bypass and open-heart surgeries. It minimizes the requirement for allogeneic blood products in adult cardiac surgery. Preoperative autologous is a safe and efficient option for allogeneic transfusion. Patients suffering from rare blood phenotypes or allogeneic antibodies is expected to benefit from autologous transfusion as compatible allogeneic blood may not be always available.

Allogeneic transfusion is associated with potential complications that can be removed or reduced while autologous blood is administered. These complications include alloimmunization, transfusion-transmitted infectious diseases, hemolytic reactions, and allergic and febrile reactions. The withdrawal of autologous blood earlier conducting cardiopulmonary bypass preserves red cell mass protects the platelets, and decreases allogeneic transfusion needs. The appropriate condition for autologous blood donation is elective cardiac surgery where there is a high probability of blood transfusion.

Regional Outlook

The global autotransfusion systems market is further segmented based on geography, including North America (the US and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa and Latin America). The market can be analyzed for a particular region or country level as per the requirement. North America has witnessed potential in the market owing to the increasing prevalence of chronic diseases, including CVD and cancer, and significant blood management programs in the programs. Several universities and hospitals have focused on blood management programs to maintain safety and efficiency in the procedure. For instance, in 2010, Mayo Clinic implemented a patient blood-management program and has since experienced a 35%decrease in blood transfusions, increasing patient outcomes and achieving considerable savings. This, in turn, is contributing to the demand for autotransfusion systems to reduce the need for donated blood and eliminates the detrimental effects of allogeneic transfusion.

Asia-Pacific is expected to witness significant growth during the forecast period

Asia-Pacific is estimated to show significant growth during the forecast period owing to the increasing number of multi-specialty hospitals and rising incidences of orthopedic and CVD in the region. In addition, growing medical tourism is expected to offer an opportunity for market growth in the region. India Brand Equity Foundation (IBEF) estimated that the medical tourism market in India was valued at $3 billion in 2017. During the period, 2018-2019, the Indian medical tourism market is expected to double owing to the easier norms for medical visa approvals. The number of Foreign Tourist Arrivals (FTAs) in India on medical visas increased by 15.9% year-on-year to an estimated 495,056 in 2017 from 427,014 in 2016.

In India, the Joint Commission International (JCI) - accredited hospitals are 21 and are growing significantly. The presence of skilled pediatric experts in India is further attributed to the positive demand for the congenital heart disease market. As per Indian Pediatrics, currently, India has approximately 130 pediatric cardiologists and 110 pediatric cardiac surgeons. As a large number of infants are born with congenital heart defects globally, the availability of skilled cardiac surgeons and cost-effective and reliable treatment is estimated to contribute to the growth of medical tourism in the country. This, in turn, is encouraging hospitals to focus on patient safety and thereby contributing to the demand for autotransfusion systems to manage patients' blood.

Market Players Outlook

The major players in the market include Medtronic plc, Fresenius Kabi AG, Becton, Dickinson & Co., LivaNova PLC, and B. Braun Melsungen AG. The market players are adopting strategies such as mergers and acquisitions and product launches, to expand market share and gain a competitive advantage over their competitors. For instance, in April 2019, Ecomed Solutions launched HEMAsavR, a device for blood capture and transfer that will support medical professionals decrease complex and costly allogeneic blood transfusions. It is universally compatible with surgical suction and autologous transfusion systems, which makes it easy to integrate into current protocols. It is primarily beneficial to hospitals that perform orthopedic, cardiac, vascular, trauma, organ transplant, obstetrics/gynecology, thoracic, neurosurgery, general, and urology procedures.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. Medtronic plc
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. Fresenius KabiAG
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. Becton, Dickinson& Co.
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. LivaNova PLC
  • 3.5.1. Overview
  • 3.5.2. Financial Analysis
  • 3.5.3. SWOT Analysis
  • 3.5.4. Recent Developments
• 3.6. B. Braun Melsungen AG
  • 3.6.1. Overview
  • 3.6.2. Financial Analysis
  • 3.6.3. SWOT Analysis
  • 3.6.4. Recent Developments
• 3.7. Key Strategy Analysis

4. Market Segmentation

• 4.1. Global Autotransfusion Systems Market by Application
  • 4.1.1. Orthopedic Surgery
  • 4.1.2. Cardiac Surgery
  • 4.1.3. Trauma Procedures
  • 4.1.4. Organ Transplantation
  • 4.1.5. Other Procedures
• 4.2. Global Autotransfusion Systems Market by Type
  • 4.2.1. Autotransfusion Products
  • 4.2.2. Accessories

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World

6. Company Profiles

• 6.1. Advancis Surgical
• 6.2. Atrium Medical Corp.
• 6.3. B. Braun Melsungen AG
• 6.4. Becton, Dickinson and Co.
• 6.5. Beijing ZKSK Technology Co., Ltd.
• 6.6. BraileBiomedica
• 6.7. Brightwake Ltd.
• 6.8. Ecomed Solutions, LLC
• 6.9. Fresenius KabiAG
• 6.10. Gen World Medical Devices
• 6.11. Getinge AB
• 6.12. Haemonetics Corp.
• 6.13. LivaNova PLC
• 6.14. Medtronic plc
• 6.15. Palex Medical SA
• 6.16. RedaxS.p.a.
• 6.17. Sarstedt Ag & Co. KG
• 6.18. Stryker Corp.
• 6.19. Teleflex Inc.
• 6.20. Terumo Corp.
• 6.21. Zimmer Biomet Holdings, Inc.